Antagonism of intracerebrally induced nicotinic convulsions in mice: a method for measuring the central antinicotinic activity of CNS acting agents.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use; D001285:Atropine / Q000627:therapeutic use; D001681:Biological Assay; D001921:Brain / Q000378:metabolism; D002628:Chemoreceptor Cells / Q000187:drug effects; D002714:Chlorisondamine / Q000627:therapeutic use; D002746:Chlorpromazine / Q000627:therapeutic use; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D007278:Injections, Spinal; D008297:Male; D051379:Mice; D009538:Nicotine / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D010276:Parasympatholytics / Q000627:therapeutic use; D012640:Seizures / Q000139:chemically induced / Q000188:drug therapy*; D013565:Sympatholytics / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000927:Anticonvulsants; D000928:Antidepressive Agents; D006634:Histamine H1 Antagonists; D010276:Parasympatholytics; D013565:Sympatholytics; D009538:Nicotine; D001285:Atropine; D002714:Chlorisondamine; D002746:Chlorpromazine